Table 4 Logistic regression model: abandonment of initial oncolytic prescription
From: Impact of pharmacy channel on adherence to oral oncolytics
Determinant | Odds Ratio | 95% CI |
|---|---|---|
Age, Reference <65 years | ||
≥ 65 years | 1.25 | 1.04–1.51 |
Gender, Reference Female | ||
Male | 1.16 | 0.99–1.36 |
Geographic Region, Reference South | ||
Northeast | 0.64 | 0.51–0.81 |
Midwest | 1.10 | 0.90–1.35 |
West | 1.00 | 0.78–1.27 |
Other/missing | 1.48 | 1.01–2.17 |
Population, Reference Retail Pharmacy | ||
Specialty | 0.44 | 0.35–0.55 |
Copay, Reference $0–49 | ||
$50–100 | 1.55 | 1.14–2.12 |
$101–150 | 1.55 | 1.02–2.35 |
$151–200 | 1.94 | 1.17–3.24 |
$201–250 | 3.43 | 2.15–5.47 |
$251–350 | 4.54 | 3.00–6.93 |
$351–500 | 5.22 | 3.65–7.46 |
$501–1000 | 4.89 | 3.71–6.44 |
> $1000 | 13.69 | 10.87–17.23 |
Index Oncolytic, Reference Erlotinib | ||
Capecitabine | 1.41 | 1.15-1.74 |
Imatinib | 0.94 | 0.73-1.22 |